Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Restoring the Patient's Voice Act of 2017
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - support for existing programs HR 4710 - 340B Pause Act - education on 340B program and impact on patient access S 2453 - Ensuring the Value of the 340B program - education on 340B program and impact on patient access S 2554 - Patient Right to Know Drug Prices Act (Gag rule) Education around patient access to prescribed medicines
Restoring the Patient's Voice Act of 2017
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ALLIANCE FOR PATIENT ACCESS via WOODBERRY ASSOCIATES
2019 · first_quarter · 1T
Step Therapy reform Medicare Part D - six protected classes Medicare Part B - education on program and CMS reform proposals Clinical Trials funding and participation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR PATIENT ACCESS via WOODBERRY ASSOCIATES
2018 · fourth_quarter · Q4
Source: Senate LDA
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - support for existing programs PL 115-262 (S. 2553) - Know the Lowest Price Act of 2018 PL 115-263 (S 2554) - Patient Right to Know Drug Prices Act (Gag rule) Education around patient access to prescribed medicines
Restoring the Patient's Voice Act of 2017
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - education on CMS proposals (focused on increased usage of utilization management tools)
Restoring the Patient's Voice Act of 2017
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - support for existing programs HR 4710 - 340B Pause Act - education on 340B program and impact on patient access S 2453 - Ensuring the Value of the 340B program - education on 340B program and impact on patient access Education around patient access to prescribed medicines
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - support for existing programs HR 4710 - 340B Pause Act - education on 340B program and impact on patient access S 2453 - Ensuring the Value of the 340B program - education on 340B program and impact on patient access Education around patient access to prescribed medicines
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - support for existing programs HR 4710 - 340B Pause Act - education on 340B program and impact on patient access S 2453 - Ensuring the Value of the 340B program - education on 340B program and impact on patient access S 2554 - Patient Right to Know Drug Prices Act (Gag rule) Education around patient access to prescribed medicines
Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - support for existing programs HR 4710 - 340B Pause Act - education on 340B program and impact on patient access S 2453 - Ensuring the Value of the 340B program - education on 340B program and impact on patient access Education around patient access to prescribed medicines
Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - support for existing programs PL 115-262 (S. 2553) - Know the Lowest Price Act of 2018 PL 115-263 (S 2554) - Patient Right to Know Drug Prices Act (Gag rule) Education around patient access to prescribed medicines
Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - support for existing programs HR 4710 - 340B Pause Act - education on 340B program and impact on patient access S 2453 - Ensuring the Value of the 340B program - education on 340B program and impact on patient access S 2554 - Patient Right to Know Drug Prices Act (Gag rule) Education around patient access to prescribed medicines
Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - education on CMS proposals (focused on increased usage of utilization management tools)
Ensuring the Value of the 340B Program Act of 2018
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - support for existing programs HR 4710 - 340B Pause Act - education on 340B program and impact on patient access S 2453 - Ensuring the Value of the 340B program - education on 340B program and impact on patient access Education around patient access to prescribed medicines
Ensuring the Value of the 340B Program Act of 2018
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - support for existing programs HR 4710 - 340B Pause Act - education on 340B program and impact on patient access S 2453 - Ensuring the Value of the 340B program - education on 340B program and impact on patient access S 2554 - Patient Right to Know Drug Prices Act (Gag rule) Education around patient access to prescribed medicines
Know the Lowest Price Act of 2018
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - support for existing programs PL 115-262 (S. 2553) - Know the Lowest Price Act of 2018 PL 115-263 (S 2554) - Patient Right to Know Drug Prices Act (Gag rule) Education around patient access to prescribed medicines
Patient Right to Know Drug Prices Act
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - support for existing programs HR 4710 - 340B Pause Act - education on 340B program and impact on patient access S 2453 - Ensuring the Value of the 340B program - education on 340B program and impact on patient access S 2554 - Patient Right to Know Drug Prices Act (Gag rule) Education around patient access to prescribed medicines
Patient Right to Know Drug Prices Act
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - support for existing programs PL 115-262 (S. 2553) - Know the Lowest Price Act of 2018 PL 115-263 (S 2554) - Patient Right to Know Drug Prices Act (Gag rule) Education around patient access to prescribed medicines
Restoring the Patient's Voice Act of 2017
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) PL 115-52 FDA Reauthorization Act of 2017 - passage and inclusion of clinical trial awareness provisions HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation
Restoring the Patient's Voice Act of 2017
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation CMS Healthcare Common Procedure Coding System (HCPCS) for biosimilar medicines Education around patient access to prescribed medicines
FDA Reauthorization Act of 2017
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2430/S934 FDA Reauthorization Act of2017 - inclusion of clinical trial awareness provisions
FDA Reauthorization Act of 2017
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2430/S934 FDA Reauthorization Act of2017 - inclusion of clinical trial awareness provisions
Further Continuing and Security Assistance Appropriations Act, 2017
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
PL 114-255 (HR 34) - 21st Century Cures -- provisions supporting clinical trial research and CDC funding Senate Medical Innovation legislation Clinical Trials -- supporting a federal campaign to promote clinical trial participation Biologic medicines - supporting transparent naming, labeling and indication extrapolation PL 114-254 (HR 2028) Continuing Resolution - funding to implement provisions of the Comprehensive Addiction & Recovery Act (CARA) S. 3040 Labor/HHS/ED Appropriations - support for clinical trials and medical research
PL 114-255 (HR 34) - 21st Century Cures -- provisions supporting clinical trial research and CDC funding Senate Medical Innovation legislation Clinical Trials -- supporting a federal campaign to promote clinical trial participation Biologic medicines - supporting transparent naming, labeling and indication extrapolation PL 114-254 (HR 2028) Continuing Resolution - funding to implement provisions of the Comprehensive Addiction & Recovery Act (CARA) S. 3040 Labor/HHS/ED Appropriations - support for clinical trials and medical research
HR 5 - 21st Century Cures -- provisions supporting clinical trial research and CDC funding Senate Medical Innovation legisaltion Clinical Trials -- supporting a federal campaign to promote clinical trial participation Biologic medicines - supporting transparent naming, labeling and indication extrapolation Biologic medicines - CMS billing codes Opioid Abuse Deterrent Therapies/Funding authorization for opioid abuse treatment
HR 5 - 21st Century Cures -- provisions supporting clinical trial research and CDC funding Senate Medical Innovation legislation Clinical Trials -- supporting a federal campaign to promote clinical trial participation Biologic medicines - supporting transparent naming, labeling and indication extrapolation Biologic medicines - CMS billing codes S. 524 Comprehensive Addiction & Recovery Act (CARA) S. 3040 Labor/HHS/ED Appropriations - support for clinical trials and medical research
HR 5 - 21st Century Cures -- provisions supporting clinical trial research and CDC funding Senate Medical Innovation legislation Clinical Trials -- supporting a federal campaign to promote clinical trial participation Biologic medicines - supporting transparent naming, labeling and indication extrapolation S. 524 Comprehensive Addiction & Recovery Act (CARA) S. 3040 Labor/HHS/ED Appropriations - support for clinical trials and medical research
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
PL 114-255 (HR 34) - 21st Century Cures -- provisions supporting clinical trial research and CDC funding Senate Medical Innovation legislation Clinical Trials -- supporting a federal campaign to promote clinical trial participation Biologic medicines - supporting transparent naming, labeling and indication extrapolation PL 114-254 (HR 2028) Continuing Resolution - funding to implement provisions of the Comprehensive Addiction & Recovery Act (CARA) S. 3040 Labor/HHS/ED Appropriations - support for clinical trials and medical research
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
HR 5 - 21st Century Cures -- provisions supporting clinical trial research and CDC funding Senate Medical Innovation legislation Clinical Trials -- supporting a federal campaign to promote clinical trial participation Biologic medicines - supporting transparent naming, labeling and indication extrapolation S. 524 Comprehensive Addiction & Recovery Act (CARA) S. 3040 Labor/HHS/ED Appropriations - support for clinical trials and medical research
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
HR 5 - 21st Century Cures -- provisions supporting clinical trial research and CDC funding Senate Medical Innovation legislation Clinical Trials -- supporting a federal campaign to promote clinical trial participation Biologic medicines - supporting transparent naming, labeling and indication extrapolation Biologic medicines - CMS billing codes S. 524 Comprehensive Addiction & Recovery Act (CARA) S. 3040 Labor/HHS/ED Appropriations - support for clinical trials and medical research
Comprehensive Addiction and Recovery Act of 2016
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
HR 5 - 21st Century Cures -- provisions supporting clinical trial research and CDC funding Senate Medical Innovation legislation Clinical Trials -- supporting a federal campaign to promote clinical trial participation Biologic medicines - supporting transparent naming, labeling and indication extrapolation Biologic medicines - CMS billing codes S. 524 Comprehensive Addiction & Recovery Act (CARA) S. 3040 Labor/HHS/ED Appropriations - support for clinical trials and medical research
Comprehensive Addiction and Recovery Act of 2016
Client: ALLIANCE FOR PATIENT ACCESS · Firm: WOODBERRY ASSOCIATES
HR 5 - 21st Century Cures -- provisions supporting clinical trial research and CDC funding Senate Medical Innovation legislation Clinical Trials -- supporting a federal campaign to promote clinical trial participation Biologic medicines - supporting transparent naming, labeling and indication extrapolation S. 524 Comprehensive Addiction & Recovery Act (CARA) S. 3040 Labor/HHS/ED Appropriations - support for clinical trials and medical research
HR 5 - 21st Century Cures -- provisions supporting clinical trial research and CDC funding Senate Medical Innovation legisaltion Clinical Trials -- supporting a federal campaign to promote clinical trial participation Biologic medicines - supporting transparent naming, labeling and indication extrapolation Biologic medicines - CMS billing codes
HR 5 - 21st Century Cures -- provisions supporting clinical trial research and CDC funding Clinical Trials -- supporting a federal campaign to promote clinical trial participation Biologic medicines - supporting transparent naming, labeling and indication extrapolation
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - education on CMS proposals (focused on increased usage of utilization management tools)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR PATIENT ACCESS via WOODBERRY ASSOCIATES
2018 · third_quarter · Q3
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - support for existing programs PL 115-262 (S. 2553) - Know the Lowest Price Act of 2018 PL 115-263 (S 2554) - Patient Right to Know Drug Prices Act (Gag rule) Education around patient access to prescribed medicines
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR PATIENT ACCESS via WOODBERRY ASSOCIATES
2018 · second_quarter · Q2
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - support for existing programs HR 4710 - 340B Pause Act - education on 340B program and impact on patient access S 2453 - Ensuring the Value of the 340B program - education on 340B program and impact on patient access S 2554 - Patient Right to Know Drug Prices Act (Gag rule) Education around patient access to prescribed medicines
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR PATIENT ACCESS via WOODBERRY ASSOCIATES
2018 · first_quarter · Q1
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation HR 4841 - Safe Prescribing Act of 2018 - support for standardizing electronic prior authorization for medicare Part D Medicare Part B and Part D - support for existing programs HR 4710 - 340B Pause Act - education on 340B program and impact on patient access S 2453 - Ensuring the Value of the 340B program - education on 340B program and impact on patient access Education around patient access to prescribed medicines
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR PATIENT ACCESS via WOODBERRY ASSOCIATES
2017 · fourth_quarter · Q4
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation CMS Healthcare Common Procedure Coding System (HCPCS) for biosimilar medicines Education around patient access to prescribed medicines
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR PATIENT ACCESS via WOODBERRY ASSOCIATES
2017 · third_quarter · Q3
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) PL 115-52 FDA Reauthorization Act of 2017 - passage and inclusion of clinical trial awareness provisions HR 2077 - Restoring the Patient's Voice Act of 2017 - support for federal step therapy legislation
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR PATIENT ACCESS via WOODBERRY ASSOCIATES
2017 · second_quarter · Q2
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) HR 2430/S934 FDA Reauthorization Act of2017 - inclusion of clinical trial awareness provisions
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR PATIENT ACCESS via WOODBERRY ASSOCIATES
2017 · first_quarter · Q1
Biologic and biosimilar medicines - access and uptake (education on FDA guidelines) Prescription Drug Use Fee Act (PDUFA) - inclusion of clinical trial awareness provisions
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR PATIENT ACCESS via WOODBERRY ASSOCIATES
2016 · fourth_quarter · Q4
PL 114-255 (HR 34) - 21st Century Cures -- provisions supporting clinical trial research and CDC funding Senate Medical Innovation legislation Clinical Trials -- supporting a federal campaign to promote clinical trial participation Biologic medicines - supporting transparent naming, labeling and indication extrapolation PL 114-254 (HR 2028) Continuing Resolution - funding to implement provisions of the Comprehensive Addiction & Recovery Act (CARA) S. 3040 Labor/HHS/ED Appropriations - support for clinical trials and medical research
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR PATIENT ACCESS via WOODBERRY ASSOCIATES
2016 · third_quarter · Q3
HR 5 - 21st Century Cures -- provisions supporting clinical trial research and CDC funding Senate Medical Innovation legislation Clinical Trials -- supporting a federal campaign to promote clinical trial participation Biologic medicines - supporting transparent naming, labeling and indication extrapolation S. 524 Comprehensive Addiction & Recovery Act (CARA) S. 3040 Labor/HHS/ED Appropriations - support for clinical trials and medical research
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR PATIENT ACCESS via WOODBERRY ASSOCIATES
2016 · second_quarter · Q2
HR 5 - 21st Century Cures -- provisions supporting clinical trial research and CDC funding Senate Medical Innovation legislation Clinical Trials -- supporting a federal campaign to promote clinical trial participation Biologic medicines - supporting transparent naming, labeling and indication extrapolation Biologic medicines - CMS billing codes S. 524 Comprehensive Addiction & Recovery Act (CARA) S. 3040 Labor/HHS/ED Appropriations - support for clinical trials and medical research
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR PATIENT ACCESS via WOODBERRY ASSOCIATES
2016 · first_quarter · Q1
HR 5 - 21st Century Cures -- provisions supporting clinical trial research and CDC funding Senate Medical Innovation legisaltion Clinical Trials -- supporting a federal campaign to promote clinical trial participation Biologic medicines - supporting transparent naming, labeling and indication extrapolation Biologic medicines - CMS billing codes Opioid Abuse Deterrent Therapies/Funding authorization for opioid abuse treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR PATIENT ACCESS via WOODBERRY ASSOCIATES
2015 · fourth_quarter · Q4
HR 5 - 21st Century Cures -- provisions supporting clinical trial research and CDC funding Senate Medical Innovation legisaltion Clinical Trials -- supporting a federal campaign to promote clinical trial participation Biologic medicines - supporting transparent naming, labeling and indication extrapolation Biologic medicines - CMS billing codes
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR PATIENT ACCESS via WOODBERRY ASSOCIATES
2015 · third_quarter · Q3
HR 5 - 21st Century Cures -- provisions supporting clinical trial research and CDC funding Clinical Trials -- supporting a federal campaign to promote clinical trial participation Biologic medicines - supporting transparent naming, labeling and indication extrapolation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE